May 2011 Latest GU Updates from ASCO GU

Published: Tue May 31, 2011 Updated:Sat Jan 28, 2012

We would like to thank Dr Lori Wood for the latest GU update.

 

Subgroup Analysis Update:

Abiraterone acetate (AA) plus low dose prednisone improves overall survival in patients with metastatic castration resistant prostate cancer (CRPCa) who have progress after docetaxel-based chemotherapy: Results of COU-AA-301, a randomized double-blind placebo-controlled phase III study.

 

 

Member Comments (0)

This thread has been closed from taking new comments.

Sign-up for Our E-Newsletter